TCY-NH2
TCY-NH2 Basic information
- Product Name:
- TCY-NH2
- Synonyms:
-
- TCY-NH2
- TRANS-CINNAMOYL-TYR-PRO-GLY-LYS-PHE-NH2
- TRANS-CINNAMOYL-YPGKF-AMIDE
- M.W. 739.87 C40H49N7O7
- trans-Cinnamoyl-Tyr-Pro-Gly-Lys-Phe-amide trifluoroacetate salt
- trans-Cinnamoyl-YPGKF-NH2, tcY-NH2
- trans-Cinnamoyl-YPGKF-NH2
- L-Phenylalaninamide, N-[(2E)-1-oxo-3-phenyl-2-propen-1-yl]-L-tyrosyl-L-prolylglycyl-L-lysyl-
- CAS:
- 327177-34-4
- MF:
- C40H49N7O7
- MW:
- 739.86
- Product Categories:
-
- Proteinase-activated receptor (PAR)
- Mol File:
- 327177-34-4.mol
More
Less
TCY-NH2 Chemical Properties
- storage temp.
- −20°C
- form
- Powder
- Water Solubility
- Soluble to 1 mg/ml in water
More
Less
Safety Information
- Safety Statements
- 22-24/25
More
Less
TCY-NH2 Usage And Synthesis
Uses
tcY-NH2 does not cause aggregation but blocks aggregation caused by receptor-activating peptide analogs (GY-NH2, AY-NH2), and thrombin without affecting ADP-mediated aggregation.
in vivo
tcY-NH2 (tail vein injection, 0.6 mg/kg for a single dose) alleviates liver injury in Brain death (BD) rat model, indicated by lower serum ALT/AST levels and better histomorphology[3].
tcY-NH2 (intraperitoneal injection, 0.6 mg/kg for a single dose) increases posttraumatic activation of CD4+ Tregs within the draining lymph nodes in burn injury mice model [4].
tcY-NH2 (intrapleural injection, 40 ng/kg for a single dose) inhibits neutrophil recruitment in experimental inflammation in mice[6].
| Animal Model: | Brain death (BD) rat model[3] |
| Dosage: | 0.6 mg/kg for a single dose |
| Administration: | Tail vein injection for a single dose |
| Result: | Reduced blood platelet activation and hepatic platelet accumulation. Attenuated the inflammatory response and apoptosis in the livers. Inhibited the activation of NF-κB and MAPK pathways induced by Brain death (BD). |
| Animal Model: | Burn injury model of C57BL/6 N mice[4] |
| Dosage: | 0.6 mg/kg for a single dose |
| Administration: | Intraperitoneal injection |
| Result: | Increased expression and phosphorylation of PKC-θ in the presence of platelets, without affecting early posttraumatic hemostasis. |
| Animal Model: | BALB/c mice[6] |
| Dosage: | 40 ng/kg for a single dose |
| Administration: | Intrapleural injection |
| Result: | Abolished the number of rolling and adhering neutrophils on the vessel wall. Inhibited CXCL8- and Cg-induced neutrophil migration into the pleural cavity of mice. |
IC 50
PAR4
storage
Store at -20°C
TCY-NH2Supplier
3B Pharmachem (Wuhan) International Co.,Ltd.
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
Creative Peptides
- Tel
- info@creative-peptides.com
Hangzhou Peptidego Biotech Co.,Ltd.
- Tel
- 0571-87213919
- Eric@peptidego.com
Zhejiang J&C Biological Technology Co.,Limited
- Tel
- +1-2135480471
- sales@sarms4muscle.com
BOC Sciences
- Tel
- info@bocsci.com